3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
24
Gastrointestinal
16
Genitourinary
13
Other
8
Other hematologic neoplasm
6
Head & Neck
6
Thoracic
5
Lymphoid
5
Plasma cell
4
Gynecologic
4
CNS
4
Tumor-Agnostic
2
Sarcoma
2
Endocrine
2
Other solid neoplasm
1
Myeloid
1
Dermatologic
1
Conditions
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Motor Activity
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Cyclophosphamide
229
fludarabine phosphate
206
fludarabine
163
Busulfan
150
Mycophenolic Acid
135
Tacrolimus
133
Whole-Body Irradiation
132
Peripheral Blood Stem Cell Transplantation
121
Cytarabine
101
Azacitidine
100
Antilymphocyte Serum
98
Melphalan
96
Cyclosporine
96
Methotrexate
87
Imatinib Mesylate
87
Filgrastim
85
Decitabine
66
Granulocyte Colony-Stimulating Factor
60
Thiotepa
57
venetoclax
53
Stem Cell Transplantation
53
thymoglobulin
51
Radiotherapy
49
Cord Blood Stem Cell Transplantation
42
nilotinib
40
Clofarabine
38
Dasatinib
37
Methylprednisolone
36
ruxolitinib
35
Etoposide
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Resistance Training
×
Myeloid
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled